(Total Views: 450)
Posted On: 07/03/2025 9:49:58 PM
Post# of 154882
We have been 100% blind to the fact they have been developing the 2nd MOA for some time: a LL & ICI combo
Sept. 2024:"...will aim to confirm the mechanism of action of leronlimab in oncology and address the question of potential synergies with both antibody-drug conjugates and immune checkpoint inhibitors."
MOA video on website:
*Mentions checkpoint inhibitors
*T-cells
https://s3.amazonaws.com/content.stockpr.com/...4/cyto.mp4
Applying all benefits of LL to an ICI combo @ all solid tumor patients who upregulate,,
& what in the medical industry, can compete with that....
Nothing.
Sept. 2024:"...will aim to confirm the mechanism of action of leronlimab in oncology and address the question of potential synergies with both antibody-drug conjugates and immune checkpoint inhibitors."
MOA video on website:
*Mentions checkpoint inhibitors
*T-cells
https://s3.amazonaws.com/content.stockpr.com/...4/cyto.mp4
Applying all benefits of LL to an ICI combo @ all solid tumor patients who upregulate,,
& what in the medical industry, can compete with that....
Nothing.
(6)
(0)
